Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493504 | 0.82 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9ANPC1LMNAKMT2A | |
| SCHEMBL493514 | 0.79 | HDAC4 (0.44) | SMN1; SMN2NPC1LMNAKMT2APKM | |
| SCHEMBL493708 | 0.79 | KMT2A (0.39) | SMN1; SMN2NPC1LMNAKMT2APOLB | |
| SCHEMBL1327170 | 0.78 | RAB9A (0.49) | SMN1; SMN2RAB9ANPC1KMT2APOLB | |
| SCHEMBL1328322 | 0.76 | MAPK14 (0.45) | SMN1; SMN2RAB9ANPC1KMT2AMEN1 | |
| SCHEMBL492705 | 0.75 | OPRL1 (0.44) | — | |
| SCHEMBL493779 | 0.75 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9ANPC1LMNAKMT2A | |
| SCHEMBL16434117 | 0.75 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9ANPC1LMNAKMT2A | |
| SCHEMBL492704 | 0.74 | OPRL1 (0.44) | — | |
| SCHEMBL2310340 | 0.74 | OPRL1 (0.40) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9499533-B2 | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity | SHIONOGI & CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
| EP-2832731-A1 | AROMATIC HETEROCYCLIC FIVE-MEMBERED RING DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY | Shionogi & Co., Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | SMN1; SMN2 3980/4885RAB9A 1927/4885NPC1 971/4885 |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | SMN1; SMN2 3980/4885RAB9A 1927/4885NPC1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.